Drug safety is a barrier to the discovery and development of new androgen receptor antagonists
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Androgen receptor (AR) antagonists are part of the standard of care for prostate cancer. Despite the almost inevitable development of resistance in prostate tumors to AR antagonists, no new AR antagonists have been approved for over a decade. Treatment failure is due in part to mutations that increase activity of AR in response to lower ligand concentrations as well as to mutations that result in AR response to a broader range of ligands. The failure to discover new AR antagonists has occurred in the face of continued research; to enable progress, a clear understanding of the reasons for failure is required. METHODS: Non‐clinical drug safety studies and safety pharmacology assays were performed on previously approved AR antagonists (bicalutamide, flutamide, nilutamide), next generation antagonists in clinical testing (MDV3100, BMS‐641988), and a pre‐clinical drug candidate (BMS‐501949). In addition, non‐clinical studies with AR mutant mice, and EEG recordings in rats were performed. Non‐clinical findings are compared to disclosures of clinical trial results. RESULTS: As a drug class, AR antagonists cause seizure in animals by an off‐target mechanism and are found in vitro to inhibit GABA‐A currents. Clinical trials of candidate next generation AR antagonists identify seizure as a clinical safety risk. CONCLUSIONS: Non‐clinical drug safety profiles of the AR antagonist drug class create a significant barrier to the identification of next generation AR antagonists. GABA‐A inhibition is a common off‐target activity of approved and next generation AR antagonists potentially explaining some side effects and safety hazards of this class of drugs. Prostate 77:480–488, 2011. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292 · cited 15×
“The maximum clinical dose for MDV3100 is the highest reported for which more than three patients were evaluated [21]. system, drug side effects where GABApathways could play a role include nilutamide-related decreases in visual adaptation to darkness and electroretinogram changes [12] and the increased incidence of co…”
BackgroundMethodInfluentialEndogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
Hosie, A. M., Wilkins, M. E., da Silva, H. M. A., & Smart, T. G. (2006) · Nature · doi:10.1038/nature05324 · Cited by 752 · cited 1×
“If binding of these small molecules to the GABA-A channel mimicked that of endogenous steroids [17,18], an allosteric ‘‘target-related’’ mechanism of inhibition may be invoked.”
BackgroundAkk, G., Bracamontes, J., & Steinbach, J. H. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.0673e.x · Cited by 137 · cited 1×
“If binding of these small molecules to the GABA-A channel mimicked that of endogenous steroids [17,18], an allosteric ‘‘target-related’’ mechanism of inhibition may be invoked.”
Background
Cited by
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Androgen receptor: structure, role in prostate cancer and drug discovery
Tan, M. E., Li, J., Xu, H. E., Melcher, K., & Yong, E.-L. (2015) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 943
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., Chen, Y., Grillot, K., Bischoff, E. D., Cai, L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3948 · Cited by 662
Joseph, J. D., Lu, N., Qian, J., Sensintaffar, J., Shao, G., Brigham, D., Moon, M., Maneval, E. C., Chen, I., Darimont, B., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0226 · Cited by 578
Moilanen, A.-M., Riikonen, R., Oksala, R., Ravanti, L., Aho, E., Wohlfahrt, G., Nykänen, P. S., Törmäkangas, O. P., Palvimo, J. J., & Kallio, P. J. (2015) · Scientific Reports · doi:10.1038/srep12007 · Cited by 379
Metadata
- Authors
- Foster, W. R., Car, B. D., Shi, H., Levesque, P. C., Obermeier, M. T., Gan, J., Arezzo, J. C., Powlin, S. S., Dinchuk, J. E., Balog, A., Salvati, M. E., Attar, R. M., & Gottardis, M. M.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2010-09-28
- Volume
- 71
- Issue
- 5
- Pages
- 480-488
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W1985580668
- Cited by
- 118
- References
- 3
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. https://app.cochat.ai/papers/10.1002/pros.21263
- The paper
- Foster, W. R., Car, B. D., Shi, H., Levesque, P. C., Obermeier, M. T., Gan, J., Arezzo, J. C., Powlin, S. S., Dinchuk, J. E., Balog, A., Salvati, M. E., Attar, R. M., & Gottardis, M. M. (2011). Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. The Prostate. https://doi.org/10.1002/pros.21263
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.